Actym Therapeutics

Actym Therapeutics, Inc. was founded in 2017 in Berkeley, California, and is engaged in developing cancer treatments.Actym Therapeutics specializes in innovative cancer treatments through its STACT™ (S. Typhimurium Anti-Cancer Therapy) platform, which leverages engineered bacterial delivery systems. This platform allows for the systemic administration of therapeutic payloads, specifically designed to amplify and produce therapeutic agents at the disease site, minimizing the systemic toxicity commonly associated with traditional delivery methods. Actym's flagship product, ACTM-838, is currently undergoing evaluation in a phase 1a/1b clinical trial targeting patients with advanced solid tumors.Actym Therapeutics generates revenue through strategic partnerships and clinical trial collaborations aimed at advancing its proprietary therapies. Transactions typically occur on a business-to-business (B2B) basis, involving healthcare institutions and pharmaceutical companies that may seek to integrate Actym’s innovative therapies into their treatment protocols. These collaborations often involve milestone payments tied to the progress of clinical trials, along with potential licensing agreements for the use of Actym’s technology in various therapeutic applications.In June 2023, Actym Therapeutics, Inc. Furthermore, Actym plans to explore opportunities in new geographical markets, particularly targeting Europe and Asia, by 2024, as it seeks to enhance its presence in the oncology treatment landscape.

1. Series A

   Jun 28, 2023

   Amount

   $11M

   Investors

   Locked

2. Series A

   Mar 27, 2020

   Amount

   $14M

   Investors

   Locked